Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Winner
Salix Pharmaceuticals (SLXP) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, Salix Pharmaceuticals rose $2.52 (5.1%) to $52.12 on heavy volume. Throughout the day, 1.7 million shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 889,900 shares. The stock ranged in a price between $50.48-$52.74 after having opened the day at $51.16 as compared to the previous trading day's close of $49.60. Other companies within the Health Care sector that increased today were: Arena Pharmaceuticals (ARNA), up 25.7%, Savient Pharmaceuticals (SVNT), up 16.7%, IsoRay (ISR), up 14%, and K-V Pharmaceutical Company (KV.B), up 11.7%. Salix Pharmaceuticals, Ltd. acquires, develops, and markets prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $2.81 billion and is part of the drugs industry. The company has a P/E ratio of 33.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 3.7% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold. TheStreet Ratings rates Salix Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Salix Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV